December 19, 2023
October 12, 2023
October 04, 2023
September 18, 2023
August 15, 2023
June 17, 2023
May 23, 2023
May 3, 2023
April 1, 2023
September 1, 2022
November 29-December 2,2022
July 31-August 4, 2022
MEDIA CONTACT
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 1-800-824-5135
media@biomedind.com
http://www.biomedind.com
For further information about our products, please contact us. Contact us
Traneuroci™ or NA-831 provides neuroprotection and catalyzes the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
Biomed Digital is harnessing the power of wearable technology and machine learning to create a digital phenotype that helps clinicians diagnose early onset of Alzheimer’s disease.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also plan Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug designed to regenerate new neurons and reduce muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
The MICROS is a controlled release infusion system which has been approved for marketing in the US. It is used for intravenous administration of injectable drugs. NA-704 can be administered via the MICROS at home care settings. It is an accurate, safe and cost effective drug delivery system.
Learn more
In addition to Alzheimer's Disease, NA-831 shows promise as a treatment for MDD due to its neuroprotective properties. Results of a Phase 1B study have demonstrated a clean safety profile with no adverse side effects.
Learn more
